^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR1 rearrangement

    i
    Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
    Entrez ID:
    2260
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) (NCT03011372)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    04/25/2017
    Primary completion :
    07/31/2024
    Completion :
    07/31/2024
    FGFR1
    |
    FGFR1 rearrangement
    |
    Pemazyre (pemigatinib)
    Futibatinib in Patients With Specific FGFR Aberrations (NCT04189445)
    Phase 2
    Taiho Oncology, Inc.
    Active, not recruiting
    Last update posted :
    04/11/2024
    Initiation :
    08/24/2020
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    FGFR2
    |
    FGFR2 amplification • FGFR1 rearrangement
    |
    Lytgobi (futibatinib)
    Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) (NCT05267106)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    01/19/2024
    Initiation :
    05/20/2022
    Primary completion :
    11/29/2024
    Completion :
    11/29/2024
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement
    |
    Pemazyre (pemigatinib)
    Tagraxofusp (SL-401) in Patients With CMML or MF (Study 0314) (NCT02268253)
    Phase 2
    Stemline Therapeutics, Inc.
    Completed
    Last update posted :
    03/21/2023
    Initiation :
    12/01/2014
    Primary completion :
    03/07/2023
    Completion :
    03/07/2023
    PDGFRA • JAK2 • PDGFRB • PCM1
    |
    FGFR1 rearrangement
    |
    Elzonris (tagraxofusp-erzs)
    Olverembatinib for FGFR1-rearranged Neoplasms (NCT05521204)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    08/30/2022
    Initiation :
    09/01/2022
    Primary completion :
    08/31/2024
    Completion :
    08/31/2027
    FGFR1
    |
    FGFR1 rearrangement
    |
    Nailike (olverembatinib)